|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM260444421 |
| 003 |
DE-627 |
| 005 |
20231224193422.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.05.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0868.xml
|
| 035 |
|
|
|a (DE-627)NLM260444421
|
| 035 |
|
|
|a (NLM)27189717
|
| 035 |
|
|
|a (PII)S1521-6616(16)30078-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Huijts, Charlotte M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2017
|
| 500 |
|
|
|a Date Revised 04.12.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The PI3K/mTOR pathway is commonly deregulated in cancer. mTOR inhibitors are registered for the treatment of several solid tumors and novel inhibitors are explored clinically. Notably, this pathway also plays an important role in immunoregulation. While mTOR inhibitors block cell cycle progression of conventional T cells (Tconv), they also result in the expansion of CD4(+)CD25(hi)FOXP3(+) regulatory T cells (Tregs), and this likely limits their clinical antitumor efficacy. Here, we compared the effects of dual mTOR/PI3K inhibition (using BEZ235) to single PI3K (using BKM120) or mTOR inhibition (using rapamycin and everolimus) on Treg expansion and functionality. Whereas rapamycin, everolimus and BEZ235 effected a relative expansion benefit for Tregs and increased their overall suppressive activity, BKM120 allowed for similar expansion rates of Tregs and Tconv without altering their overall suppressive activity. Therefore, PI3K inhibition alone might offer antitumor efficacy without the detrimental selective expansion of Tregs associated with mTOR inhibition
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a PI3K
|
| 650 |
|
4 |
|a Rapamycin
|
| 650 |
|
4 |
|a Treg
|
| 650 |
|
4 |
|a mTOR
|
| 650 |
|
7 |
|a Aminopyridines
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Imidazoles
|2 NLM
|
| 650 |
|
7 |
|a Morpholines
|2 NLM
|
| 650 |
|
7 |
|a NVP-BKM120
|2 NLM
|
| 650 |
|
7 |
|a Phosphoinositide-3 Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Quinolines
|2 NLM
|
| 650 |
|
7 |
|a Everolimus
|2 NLM
|
| 650 |
|
7 |
|a 9HW64Q8G6G
|2 NLM
|
| 650 |
|
7 |
|a MTOR protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.1.1
|2 NLM
|
| 650 |
|
7 |
|a TOR Serine-Threonine Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a dactolisib
|2 NLM
|
| 650 |
|
7 |
|a RUJ6Z9Y0DT
|2 NLM
|
| 650 |
|
7 |
|a Sirolimus
|2 NLM
|
| 650 |
|
7 |
|a W36ZG6FT64
|2 NLM
|
| 700 |
1 |
|
|a Santegoets, Saskia J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Quiles Del Rey, Maria
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Haas, Richard R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Verheul, Henk M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Gruijl, Tanja D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van der Vliet, Hans J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 168(2016) vom: 18. Juli, Seite 47-54
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:168
|g year:2016
|g day:18
|g month:07
|g pages:47-54
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.05.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 168
|j 2016
|b 18
|c 07
|h 47-54
|